• Elenore P Bhatraju, Natasha Ludwig-Barron, Julian Takagi-Stewart, Harveen K Sandhu, KleinJared WJWDivision of General Internal Medicine, University of Washington, Seattle, WA, United States., and Judith I Tsui.
• Division of General Internal Medicine, University of Washington, Seattle, WA, United States. Electronic address: epb6@uw.edu.
• Drug Alcohol Depend. 2020 Oct 1; 215: 108253.

BackgroundThe opioid epidemic continues to cause significant morbidity and mortality. Although there are effective medications for opioid use disorder (OUD), a minority of patients receive these treatments. OUD is common among patients hospitalized for traumatic injury and hospitalization could be an opportunity to initiate medications and link to ongoing buprenorphine care.MethodsThis retrospective cohort study based on electronic health record review included patients who were: (1) hospitalized between January 1, 2018 and June 30, 2019, (2) age ≥18 years, (3) seen by an Addiction Medicine Consult Service, and (4) initiated on buprenorphine with plans for continuation post-discharge. Descriptive statistics identified differences between trauma and non-trauma groups and regression analysis identified predictors of 30 day buprenorphine follow up.ResultsOf 197 eligible patients, 60 (30.5 %) were hospitalized for traumatic injuries. Compared to non-trauma patients, trauma patients were younger, more likely to be employed, more likely to report using cannabis and tobacco, less likely to have recently injected drugs, and hospitalized longer. Among patients with follow-up data available (n = 147), 63.2 % of trauma patients were seen within 30 days, compared to 48.2 % of non-trauma patients (p = 0.16). There were no significant differences between the two groups with regards to urine drug test results or acute care utilization in the follow-up period.ConclusionsAmong hospitalized patients with OUD who initiate buprenorphine, those who were hospitalized for trauma were at least as likely to link to out-patient treatment. Trauma admissions represent an important opportunity for diagnosing and linking patients with OUD to buprenorphine treatment.Copyright © 2020. Published by Elsevier B.V.

22 keywords...

hide…